[A case report of malignant lymphoma receiving infliximab therapy with Behçet's disease].

Koh Hei Sonoda, Takako Fukuhara, Horoshi Yoshikawa, Atsunobu Takeda, Takeru Yoshimura, Mitsuteru Akahoshi, Hirotake Kusumoto, Kentaro Kohno, Koji Kato, Koichi Akashi, Kenichi Kohashi, Shinichi Aijima, Kenichi Namba, Tatsuro Ishibashi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To report a case of malignant lymphoma occurring in Behçet's disease (BD) with infliximab therapy. A 62-year-old man was diagnosed with BD in 1997. Despite treatment with colchicine, cyclosporine and prednisolone, he had frequent bilateral posterior ocular attacks. He was started on infliximab in August 2007 and for 6 months had no ocular attacks. Cyclosporine was therefore reduced. After 4 years of infliximab administration, he had neither ocular attacks nor general symptoms. However, he had general malaise and weight loss from the end of March 2012. Peripheral blood examination showed abnormal cells, so we terminated the infliximab. Bone marrow aspiration showed diffuse proliferation of medium to large lymphoid cells, and the histological diagnosis was diffuse large B-cell lymphoma. He was treated with 8 cycles of chemotherapy and 4 times intrathecal chemotherapy, and is now in remission. After termination of infliximab, he had no further ocular attacks. Although malignant lymphoma associated with BD is rare, attending ophthalmologists need to keep it in mind.

Original languageEnglish
Pages (from-to)440-445
Number of pages6
JournalNippon Ganka Gakkai zasshi
Volume118
Issue number5
Publication statusPublished - May 2014

Fingerprint

Lymphoma
Cyclosporine
Therapeutics
Drug Therapy
Lymphoma, Large B-Cell, Diffuse
Colchicine
Rare Diseases
Prednisolone
Weight Loss
Bone Marrow
Infliximab
Lymphocytes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

[A case report of malignant lymphoma receiving infliximab therapy with Behçet's disease]. / Sonoda, Koh Hei; Fukuhara, Takako; Yoshikawa, Horoshi; Takeda, Atsunobu; Yoshimura, Takeru; Akahoshi, Mitsuteru; Kusumoto, Hirotake; Kohno, Kentaro; Kato, Koji; Akashi, Koichi; Kohashi, Kenichi; Aijima, Shinichi; Namba, Kenichi; Ishibashi, Tatsuro.

In: Nippon Ganka Gakkai zasshi, Vol. 118, No. 5, 05.2014, p. 440-445.

Research output: Contribution to journalArticle

Sonoda, KH, Fukuhara, T, Yoshikawa, H, Takeda, A, Yoshimura, T, Akahoshi, M, Kusumoto, H, Kohno, K, Kato, K, Akashi, K, Kohashi, K, Aijima, S, Namba, K & Ishibashi, T 2014, '[A case report of malignant lymphoma receiving infliximab therapy with Behçet's disease].', Nippon Ganka Gakkai zasshi, vol. 118, no. 5, pp. 440-445.
Sonoda, Koh Hei ; Fukuhara, Takako ; Yoshikawa, Horoshi ; Takeda, Atsunobu ; Yoshimura, Takeru ; Akahoshi, Mitsuteru ; Kusumoto, Hirotake ; Kohno, Kentaro ; Kato, Koji ; Akashi, Koichi ; Kohashi, Kenichi ; Aijima, Shinichi ; Namba, Kenichi ; Ishibashi, Tatsuro. / [A case report of malignant lymphoma receiving infliximab therapy with Behçet's disease]. In: Nippon Ganka Gakkai zasshi. 2014 ; Vol. 118, No. 5. pp. 440-445.
@article{210341f6d93c45e596a0270aaec32444,
title = "[A case report of malignant lymphoma receiving infliximab therapy with Beh{\cc}et's disease].",
abstract = "To report a case of malignant lymphoma occurring in Beh{\cc}et's disease (BD) with infliximab therapy. A 62-year-old man was diagnosed with BD in 1997. Despite treatment with colchicine, cyclosporine and prednisolone, he had frequent bilateral posterior ocular attacks. He was started on infliximab in August 2007 and for 6 months had no ocular attacks. Cyclosporine was therefore reduced. After 4 years of infliximab administration, he had neither ocular attacks nor general symptoms. However, he had general malaise and weight loss from the end of March 2012. Peripheral blood examination showed abnormal cells, so we terminated the infliximab. Bone marrow aspiration showed diffuse proliferation of medium to large lymphoid cells, and the histological diagnosis was diffuse large B-cell lymphoma. He was treated with 8 cycles of chemotherapy and 4 times intrathecal chemotherapy, and is now in remission. After termination of infliximab, he had no further ocular attacks. Although malignant lymphoma associated with BD is rare, attending ophthalmologists need to keep it in mind.",
author = "Sonoda, {Koh Hei} and Takako Fukuhara and Horoshi Yoshikawa and Atsunobu Takeda and Takeru Yoshimura and Mitsuteru Akahoshi and Hirotake Kusumoto and Kentaro Kohno and Koji Kato and Koichi Akashi and Kenichi Kohashi and Shinichi Aijima and Kenichi Namba and Tatsuro Ishibashi",
year = "2014",
month = "5",
language = "English",
volume = "118",
pages = "440--445",
journal = "Journal of Japanese Ophthalmological Society",
issn = "0029-0203",
publisher = "Nippon Ganka Gakkai",
number = "5",

}

TY - JOUR

T1 - [A case report of malignant lymphoma receiving infliximab therapy with Behçet's disease].

AU - Sonoda, Koh Hei

AU - Fukuhara, Takako

AU - Yoshikawa, Horoshi

AU - Takeda, Atsunobu

AU - Yoshimura, Takeru

AU - Akahoshi, Mitsuteru

AU - Kusumoto, Hirotake

AU - Kohno, Kentaro

AU - Kato, Koji

AU - Akashi, Koichi

AU - Kohashi, Kenichi

AU - Aijima, Shinichi

AU - Namba, Kenichi

AU - Ishibashi, Tatsuro

PY - 2014/5

Y1 - 2014/5

N2 - To report a case of malignant lymphoma occurring in Behçet's disease (BD) with infliximab therapy. A 62-year-old man was diagnosed with BD in 1997. Despite treatment with colchicine, cyclosporine and prednisolone, he had frequent bilateral posterior ocular attacks. He was started on infliximab in August 2007 and for 6 months had no ocular attacks. Cyclosporine was therefore reduced. After 4 years of infliximab administration, he had neither ocular attacks nor general symptoms. However, he had general malaise and weight loss from the end of March 2012. Peripheral blood examination showed abnormal cells, so we terminated the infliximab. Bone marrow aspiration showed diffuse proliferation of medium to large lymphoid cells, and the histological diagnosis was diffuse large B-cell lymphoma. He was treated with 8 cycles of chemotherapy and 4 times intrathecal chemotherapy, and is now in remission. After termination of infliximab, he had no further ocular attacks. Although malignant lymphoma associated with BD is rare, attending ophthalmologists need to keep it in mind.

AB - To report a case of malignant lymphoma occurring in Behçet's disease (BD) with infliximab therapy. A 62-year-old man was diagnosed with BD in 1997. Despite treatment with colchicine, cyclosporine and prednisolone, he had frequent bilateral posterior ocular attacks. He was started on infliximab in August 2007 and for 6 months had no ocular attacks. Cyclosporine was therefore reduced. After 4 years of infliximab administration, he had neither ocular attacks nor general symptoms. However, he had general malaise and weight loss from the end of March 2012. Peripheral blood examination showed abnormal cells, so we terminated the infliximab. Bone marrow aspiration showed diffuse proliferation of medium to large lymphoid cells, and the histological diagnosis was diffuse large B-cell lymphoma. He was treated with 8 cycles of chemotherapy and 4 times intrathecal chemotherapy, and is now in remission. After termination of infliximab, he had no further ocular attacks. Although malignant lymphoma associated with BD is rare, attending ophthalmologists need to keep it in mind.

UR - http://www.scopus.com/inward/record.url?scp=84905576172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905576172&partnerID=8YFLogxK

M3 - Article

C2 - 25011243

AN - SCOPUS:84905576172

VL - 118

SP - 440

EP - 445

JO - Journal of Japanese Ophthalmological Society

JF - Journal of Japanese Ophthalmological Society

SN - 0029-0203

IS - 5

ER -